Cost of disease-modifying therapies for multiple sclerosis continues to rise in US
Pharmaceutical Technology
MAY 19, 2023
DMTs for MS have a high price tag, particularly in the US. For some DMTs, such as Biogen’s Tysabri (natalizumab), Sanofi’s Lemtrada (alemtuzumab), and Novartis’s Gilenya (fingolimod) and Mayzent (siponimod), the annual cost of therapy rose by as much as 12%.
246 
Let's personalize your content